<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="79044">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02050646</url>
  </required_header>
  <id_info>
    <org_study_id>1303011696</org_study_id>
    <secondary_id>YSOM Pediatrics Department</secondary_id>
    <nct_id>NCT02050646</nct_id>
  </id_info>
  <brief_title>The Role of Sodium Chloride and the Treg/Th17 Axis in Autoimmune Hepatitis</brief_title>
  <official_title>The Role of Sodium Chloride and the Treg/Th17 Axis in Autoimmune Hepatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether a salt restriction diet improves immune
      parameters in patients with autoimmune hepatitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The etiology of autoimmune hepatitis (AIH) is unknown although both genetic and
      environmental factors are thought to be involved.  A defect in immune regulation affecting
      regulatory T cells (Tregs) has been demonstrated in AIH. Tregs function in the maintenance
      of immune homeostasis by controlling autoreactive immune responses to self-antigens.

      Rationale: the western diet has been postulated as a potential environmental risk factor for
      the increasing incidence of autoimmune diseases in developed countries.  Data from the
      investigators' laboratory also suggests that increased dietary salt intake might represent
      an environmental risk factor for the development of autoimmune diseases through the
      induction of pathogenic Th17 cells. The dramatic in vitro effects of high salt on the
      induction of pathogenic Th17 cells from na√Øve human CD4 cells {Kleinewietfeld, Hafler.
      Nature. 2013 Apr 25;496(7446):518-22. doi: 10.1038/nature11868.}, and block of in vitro Treg
      suppression, in line with in vivo effects on worsening murine experimental autoimmune
      encephalomyelitis (EAE), have prompted the investigators to examine the effects of increased
      dietary sodium chloride in a human in vivo system.

      The investigators hypothesize that excess dietary salt may function as an environmental
      trigger that favors induction and expansion of pathogenic Th17 cells and leads to functional
      impairment of Tregs, thereby favoring development of autoimmunity.  The investigators aim to
      study their established in vitro model in humans by altering the salt intake in patients
      over a 20-day period.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Anticipated">April 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Change from baseline in production of pathogenic TH17 cells.</measure>
    <time_frame>26 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measuring TH17 cells by flow cytometry and qRT-PCR. There are no known normal ranges. The investigator will calculate the change by observing the difference from baseline values.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in regulatory T cell function.</measure>
    <time_frame>26 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measuring T cell function by flow cytometry. There are no known normal ranges. The investigator will calculate the change by observing the difference from baseline values.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Autoimmune Hepatitis</condition>
  <arm_group>
    <arm_group_label>Low salt/ Liberal salt Diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cross-over trial of liberal salt and low salt diet.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liberal salt/Low salt diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cross-over trial of low salt and liberal salt diet</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Low Salt Diet</intervention_name>
    <description>On Day 0, patients will be randomized to one of the two crossover liberal/low or low/liberal salt diet groups. Each subject will complete two controlled dietary phases: 10-days of low salt diet, a washout period of 3-days, and 10-days of liberal salt diet.</description>
    <arm_group_label>Low salt/ Liberal salt Diet</arm_group_label>
    <arm_group_label>Liberal salt/Low salt diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Liberal salt diet</intervention_name>
    <description>On Day 0, patients will be randomized to one of the two crossover liberal/low or low/liberal salt diet groups. Each subject will complete two controlled dietary phases: 10-days of low salt diet, a washout period of 3-days, and 10-days of liberal salt diet.</description>
    <arm_group_label>Low salt/ Liberal salt Diet</arm_group_label>
    <arm_group_label>Liberal salt/Low salt diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults 18-50 years of age

          -  Children 10-17 years of age

          -  ALT and/or ALP/GGT level &gt; 2X upper limit of normal

          -  ANA or SMA &gt;/= 1:40

          -  ANA or SMA &gt;/= 1:80

          -  or LKM &gt;/= 1:40

          -  or SLA positive

          -  IgG &gt; upper limit of normal

        Exclusion Criteria:

          -  Chronic hepatitis C

          -  Decompensated Liver Disease
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Udeme Ekong, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Udeme Ekong, MD, MPH</last_name>
      <phone>203-785-4649</phone>
      <email>udeme.ekong@yale.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lisa Nichols, BA</last_name>
      <phone>203-785-7526</phone>
      <email>lisa.nichols@yale.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Udeme Ekong, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 28, 2014</lastchanged_date>
  <firstreceived_date>November 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Autoimmune hepatitis</keyword>
  <keyword>Liver dysfunction</keyword>
  <keyword>Elevated serum auto antibodies</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Autoimmune</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
